CA
NBIX icon

Continuum Advisory’s Neurocrine Biosciences NBIX Stock Holding History

Continuum Advisory’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$70.4K Sell
418
-43,650
-99% -$6.48M 0.01% 721
2026
Q1 		$5.81M Buy
44,068
+1,517
+4% +$201K 0.56% 39
2025
Q4 		$6.04M Buy
42,551
+2,548
+6% +$369K 0.6% 40
2025
Q3 		$5.62M Buy
40,003
+3,416
+9% +$463K 0.59% 38
2025
Q2 		$4.6M Buy
36,587
+36,560
+135,407% +$4.19M 0.55% 42
2025
Q1 		$2.99K Hold
27
– – ﹤0.01% 1226
2024
Q4 		$3.69K Sell
27
-6
-18% -$742 ﹤0.01% 1211
2024
Q3 		$4.05K Buy
33
+10
+43% +$1.37K ﹤0.01% 1218
2024
Q2 		$3.17K Hold
23
– – ﹤0.01% 1190
2024
Q1 		$3.21K Buy
+23
New +$3.14K ﹤0.01% 1167

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Continuum Advisory's NBIX Position: Q2 2026 in Review

Continuum Advisory reduced its Neurocrine Biosciences (NBIX) stake by 99% in Q2 2026, selling an estimated $6.48M and leaving 418 shares worth $70.4K. The position accounts for 0.01% of the portfolio, ranked #721.

Continuum Advisory first reported a position in NBIX in Q1 2024 and has held it in 10 quarters since. The position peaked at $6.04M in Q4 2025. 778 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Continuum Advisory held 418 shares of Neurocrine Biosciences worth $70.4K as of Q2 2026.
  • Continuum Advisory sold 43,650 Neurocrine Biosciences shares in Q2 2026, an estimated $6.48M.
  • Neurocrine Biosciences made up 0.01% of Continuum Advisory's portfolio in Q2 2026, its #721 holding.
  • Continuum Advisory first reported a position in Neurocrine Biosciences in Q1 2024 and has held it in 10 quarters since.
  • Continuum Advisory's Neurocrine Biosciences position peaked at $6.04M in Q4 2025.
  • 778 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Continuum Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.